Work

Mollugin suppresses bladder cancer through parkin-associated mitophagy inhibition and immunogenic tumor microenvironment remodeling

Year: 2026
Type: article
Abstract: Background Bladder cancer remains a prevalent malignancy characterized by frequent recurrence, therapeutic resistance and limited durable responses tocurrent treatment strategies. Mollugin (Mol), a natural bioactive compound withreported antitumor activity, has not been fully characterized in bladder cancer. Methods MB49 mouse bladder cancer cells were treated with different concentrations of Mol. Transcriptomic profiling was performed to identify Molregulated biological pathways and provide mechanistic guidance for subsequent validation. ROS accumulation, cell viability, cytoskeletal alterations, mitochondrial membrane potential and ICD-associated markers were evaluated using fluorescence-based assays. Mitophagy-associated alterations were assessed by LC3/TOMM20 immunofluorescence and western blot analysis of PINK1, Parkin, HSP60, VDAC1 and TOMM20. Parkin knockdown was performed to determine the contribution of Parkin-associated mitophagy to Mol-induced cellular injury. The antitumor effects of Mol, alone or combined with systemic anti-PD-1 blockade, were evaluated in a syngeneic mouse bladder cancer model. Tumorinfiltrating T cells and macrophage phenotypes were analyzed by flow cytometry. Results Mol induced ROS accumulation, reduced cell viability and included JNK/p38 phosphorylation in MB49 bladder cancer cells in a concentration-dependent manner. Transcriptomic analysis revealed distinct gene expression profiles between PBS- and Mol-treated cells and identified enrichment of mitophagy, apoptosis, NF-κB, PI3K-Akt, MAPK and cancer-related signaling pathways. Mol reduced mitochondrial membrane potential-associated fluorescence and induced ICD-associated DAMP changes, including increased cellular CRT immunoreactivity, reduced intracellular HMGB1 staining, and increased extracellular ATP and HMGB1 levels. Mechanistically, Mol suppressed PINK1/Parkin-associated mitophagy, as demonstrated by reduced PINK1 and Parkin expression, decreased LC3–TOMM20 co-localization and accumulation of mitochondrial stress-associated proteins including HSP60, VDAC1 and TOMM20. Parkin silencing further enhanced Mol-induced ROS accumulation and cell death, supporting a protective role of Parkin-associated mitophagy in tumor cells. In vivo, Mol suppressed tumor growth, reduced tumor cell proliferation, increased tumor cell death and remodeled the tumor immune microenvironment, characterized by altered tumor-associated macrophage phenotypes and increased CD8-positive T-cell infiltration. Combination with systemic anti-PD-1 blockade further enhanced these immune-associated changes. Conclusion Mol suppresses bladder cancer by inhibiting Parkin-associated mitophagy and inducing immunogenic tumor microenvironment remodeling. These findings reveal a link between mitochondrial quality control, ICDassociated tumor injury and immune regulation, supporting Mol as a potential mitochondria-targeted and immunomodulatory therapeutic candidate for bladder cancer.
Language: English
Subfield: Cell Biology
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236224111
FWCI:
Cites: 51
Cited by:
Related to: 10
Parts: 5